Correlation between Increased Serum Vascular Endothelial Growth Factor Levels and 30-Day-Outcome After Acute Myocardial Infarction
DOI:
https://doi.org/10.24293/ijcpml.v27i3.1663Keywords:
Vascular endothelial growth factor, acute myocardial infarction, peripheral blood mononuclear cells, major adverse cardiovascular eventAbstract
Vascular Endothelial Growth Factor (VEGF) plays an important role in the process of regeneration and vascular repair. Atherogenesis and angiogenesis contribute to the formation of coronary collateral circulation as an alternative source of blood supply during the repairing process of Acute Myocardial Infarction (AMI). This study aimed to investigate the elevation of VEGF and its correlation to Peripheral Blood Mononuclear Cells (PBMC) and Major Adverse Cardiovascular st nd th Events (MACE). Serum VEGF measurements were carried out on 1 , 2 , and the 5 -day onset of angina on 20 patients using st th Chemwell Analyzer based on ELISA method. PBMC was counted on days 1 and 5 according to CBC results from Automatic Cell Counter Sysmex XN-1000i. The major adverse cardiovascular event was recorded 30 days after AMI onset. It was found nd that serum VEGF level in this study was 169.3±34.5 pg/mL on the 1st day, 217.0±49.7 pg/mL on the 2 day, and th th 249.2±48.5 pg/mL on the 5 day. Serum VEGF levels increased gradually and the highest value was found on the 5 day st (p=0.000). There was no correlation between elevated serum VEGF levels with PBMC on the 1 day (p=0.429, r=-0.035) and th the 5 day of AMI (p=0.225, r=+0.081). There was no correlation between elevated serum VEGF levels with incidence of MACE on 30 days after onset of AMI (OR=0.959, 95% CI, p=0.302). Serum VEGF concentrations are increased in Acute Myocardial Infarction and can be used as a marker of myocardial injury. However, this study was unable to prove its role in the outcome of AMIDownloads
References
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, et al. Fourth universal definition of myocardial
infarction (2018). Eur Heart J, 2019; 40: 237-269.
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, et al. 2015 ESC guidelines for the management of
acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task force
for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2016; 37: 267-315.
WHO. About cardiovascular diseases. 2015 Available from: http://www.who.int/cardiovascular_diseases/about_cvd/en/.[accessed 18 March, 2018].
Kementrian Kesehatan RI. Direktorat Jenderal Penyakit Tidak Menular. Profil penyakit tidak menular tahun 2016. Jakarta, Kementrian Kesehatan RI, 2017; 92.
Kementrian Kesehatan RI. Penyakit jantung penyebab kematian terbanyak ke-2 di Indonesia. 2019. Available from: h ttps ://www. k emk e s .go. id/ a rti c l e /view/19093000001/penyakit-jantung-penyebab-kematian-terbanyak-ke-2-di-indonesia.html. (accessed 14 June, 2021).
Wu X, Reboll MR, Korf-Klingebiel M, Wollert KC. Angiogenesis after acute myocardial infarction. ESC
Cardiovascular Research, 2021; 117: 1257-1273.
Zou J, Fei Q, Xiao H, Wang H, Liu K, et al. VEGF-A promotes angiogenesis after acute myocardial
infarction through increasing ROS production and enhancing ER stress-mediated autophagy. J Cell
Physiol, 2019; 234(10): 17690-703.
Braile M, Marcella S, Cristinziano L, Galdiero MR, Modestino L, et al. VEGF-A in cardiomyocytes and
heart diseases. Int. J. Mol. Sci, 2020; 21(15): 5294.
Gui C, Zeng ZY, Chen Q, Luo YW, Li L, Chen LL.Neuregulin-1 promotes myocardial angiogenesis in
the rat model of diabetic cardiomyopathy.Cell Physiol Biochem, 2018; 46(6): 2325-34.
Varricchi G, Lo_redo S, Galdiero MR, Marone G, Cristinziano L, et al. Innate effector cells in
angiogenesis and lymphangiogenesis. Curr. Opin. Immunol, 2018; 53: 152–160.
Abhinand CS, Raju R, Soumya SJ, Arya PS, Sudhakaran PR. VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J. Cell Commun Signal, 2016; 10: 347–354.
Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, et al. Molecular pharmacology of VEGF-A isoforms: Binding and signalling at VEGFR2. Int. J. Mol. Sci, 2018; 19: 1264.
Hoeres T, Wilhelm M, Smetak M, Holzmann E, Tanzil GS, et al. Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1. British Society for Immunology, Clinical
and Experimental Immunology, 2017; 192: 54–67.
Alfatni A, Riou M, Charles AL, Meyer A, Barnig C, et al. Peripheral blood mononuclear cells and platelets mithocondrial dysfunction, oxidative stress, and circulating mtDNA in cardiovascular diseases. J. Clin. Med, 2020; 9: 311.
Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor
signalling. Nat Rev Mol Cell Biol, 2016; 17: 611–625.
Dube KN, Thomas TM, Munshaw S, Rohling M, Riley PR, Smart N. Recapitulation of developmental
mechanisms to revascularize the ischemic heart. JCI Insight 2017; 2: e96800.
Garcia R, Bouleti C, Sirol M, Logeart D, Monnot C, et al. VEGF-A plasma levels are associated with
microvascular obstruction in patients with ST-segment elevation myocardial infarction. Int J Cardiol, 2019; 291: 19-24.
Harada K, Kikuchi R, Ishii H, Shibata Y, Suzuki S, et al. Association between the ratio of anti-angiogenic isoform of VEGF-A to total VEGF-A and adverse clinical outcomes in patients after acute myocardial infarction. Int J Cardiol Heart Vasc, 2018; 19: 3–7.
Niu J, Han X, Yin J, Zhang Z, Zhang ZT. Correlation between vascular endothelial growth factor and
long-term prognosis in patients with acute myocardial infarction. Experimental and Therapeutic Medicine, 2016; 12(1): 475-479.
Kobayashi K, Maeda K, Takefuji M, Kikuchi R, Morishita Y, et al. Dynamics of angiogenesis in ischemic areas of the infarcted heart. Sci Rep, 2017; 7: 7156.
Kurotsu S, Osakabe R, Isomi M, Tamura F, Sadahiro T, et al. Distinct expression patterns of Flk1 and Flt1 in the coronary vascular system during development and after myocardial infarction. Biochem Biophys Res Commun, 2018; 495: 884–891.
Williams AL, Khadka V, Tang M, Avelar A, Schunke KJ, et al. HIF1 mediates a switch in pyruvate kinase
isoforms after myocardial infarction. Physiol Genomics, 2018; 50: 479–494.
Howangyin KY, Zlatanova I, Pinto C, Ngkelo A, Cochain C, et al. Myeloid-epithelialreproductive receptor tyrosine kinase and milk fat globule epidermal growth factor 8 coordinately improve remodeling after myocardial infarction via local delivery of vascular endothelial growth factor. Circulation, 2016; 133: 826–839.
Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug
Discov, 2016; 15: 385–403.
Reinstadler SJ, Thiele H, Eitel I. Risk stratification by cardiac magnetic resonance imaging after ST-elevation myocardial infarction. Curr Opin Cardiol, 2015; 30: 681–9.
Tiller C, Reindl M, Holzknecht M, Klapfer M, Beck A, et al. Biomarker assessment for early infarct size
estimation in ST-elevation myocardial infarction. European Journal of Internal Medicine, 2019; 64: 57-62.
Huang A, Qi X, Cui Y, Wu Y, Zhou S, et al. Serum VEGF: Diagnostic value of acute coronary syndrome from stable angina pectoris and prognostic value of coronary artery disease. Cardiol Res Pract, 2020;
: 6786302
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
